## **Anil Korkut**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1472296/publications.pdf

Version: 2024-02-01

687363 940533 1,663 16 13 16 citations h-index g-index papers 17 17 17 4005 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell, 2018, 33, 690-705.e9.	16.8	478
2	Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. Cell Reports, 2019, 28, 1370-1384.e5.	6.4	382
3	A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-Î <sup>2</sup> Superfamily. Cell Systems, 2018, 7, 422-437.e7.	6.2	134
4	Perturbation Biology: Inferring Signaling Networks in Cellular Systems. PLoS Computational Biology, 2013, 9, e1003290.	3.2	128
5	Perturbation biology nominates upstream–downstream drug combinations in RAF inhibitor resistant melanoma cells. ELife, 2015, 4, .	6.0	95
6	Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell Systems, 2015, 1, 197-209.	6.2	94
7	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clinical Cancer Research, 2018, 24, 3366-3376.	<b>7.</b> O	73
8	CellBox: Interpretable Machine Learning for Perturbation Biology with Application to the Design of Cancer Combination Therapy. Cell Systems, 2021, 12, 128-140.e4.	6.2	67
9	Causal interactions from proteomic profiles: Molecular data meet pathway knowledge. Patterns, 2021, 2, 100257.	5.9	44
10	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. Cancer Cell, 2020, 38, 829-843.e4.	16.8	40
11	Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer. Clinical Cancer Research, 2021, 27, 1681-1694.	7.0	33
12	The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology, 2022, 75, 297-308.	7.3	32
13	Spatial Normalization of Reverse Phase Protein Array Data. PLoS ONE, 2014, 9, e97213.	2.5	23
14	Precision Combination Therapies Based on Recurrent Oncogenic Coalterations. Cancer Discovery, 2022, 12, 1542-1559.	9.4	17
15	Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clinical Cancer Research, 2021, 27, 3243-3252.	7.0	14
16	Analyzing causal relationships in proteomic profiles using CausalPath. STAR Protocols, 2021, 2, 100955.	1.2	7